Acerus Pharmaceuticals: Funding, Investors & Team (Sep 2026)

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of men’s and women’s health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories. Acerus currently has three marketed products: ESTRACE®, a product for the symptomatic relief of menopausal symptoms, is commercialized in Canada; NATESTO®, the first and only testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism, is commercialized in Canada and the U.S.; and URIVARX®, a Natural Health Product that helps reduce symptoms of hyperactive bladder such as daytime urinary frequency, urgency and nocturia. URIVARX® was recently approved by Health Canada and will be offered over-the-counter to Canadians dealing with such symptoms. Also, NATESTO® has been licensed for distribution in 29 additional countries worldwide. Marketing approvals in jurisdictions outside of North America are expected to take place over the course of the coming years. Acerus’ pipeline includes five innovative products: STENDRA®, a new chemical entity PDE5 inhibitor for the treatment of erectile dysfunction, which has been approved by the US FDA and the EU EMA and is commercialized in the US under the trade name STENDRA® and in the EU under the trade name SPEDRA®; ELEGANTTM Vaginal Moisturizer, which provides comfort to women suffering from vaginal dryness, and ELEGANTTM pH, which is a pH balanced vaginal product; GYNOFLOR™, an ultra-low dose vaginal estrogen combined with a probiotic, for which a NDS has been filed in Canada for the treatment of vaginal atrophy, restoration of vaginal flora and treatment of certain vaginal infections; and TEFINA™, a clinical stage product aimed at addressing a significant unmet need for women with female sexual dysfunction. Finally, Acerus is working on expanding its product portfolio by leveraging its proprietary delivery systems, patents and formulation expertise. As such, Acerus has a number of products in various stage of development. One of these projects relates to cannabinoids (whether synthetic or naturally derived cannabinoids) to be delivered intranasally to patients, which may have multiple possible therapeutic applications (the “Cannabinoids Initiative”). Acerus has filed patent applications on the Cannabinoids Initiative, is currently working on setting up a series of pharmacokinetic clinical trials and is actively looking at potential partnering transactions for these initiatives. Acerus operates from a Mississauga-based office, and is listed on the Toronto Stock Exchange (TSX:ASP). For more information, visit www.aceruspharma.com.

Acerus Pharmaceuticals has raised $2.0M across 1 round on record. The most recent is an undisclosed round of $2.0M announced in Dec 2022.

Acerus Pharmaceuticals' most recent funding round on record is an undisclosed round of $2.0M, announced in Dec 2022.

Ed Gudaitis is listed as CEO at Acerus Pharmaceuticals.

Acerus Pharmaceuticals is based in Mississauga, Ontario, Canada.

Acerus Pharmaceuticals is in the 11-50 employee band.

Acerus Pharmaceuticals' latest round of $2.0M is below the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.